Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0000903423-19-000311
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-08-12 17:00:08
Reporting Period:
2019-08-08
Accepted Time:
2019-08-12 17:00:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1478242 Iqvia Holdings Inc. IQV () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
860866 David Bonderman C/o Tpg Global, Llc
301 Commerce Street, Suite 3300
Fort Worth TX 76102
Yes No No No
1099776 G James Coulter C/o Tpg Global, Llc
301 Commerce Street, Suite 3300
Fort Worth TX 76102
Yes No No No
1425876 Tpg Advisors V, Inc. C/o Tpg Global, Llc
301 Commerce Street, Suite 3300
Fort Worth TX 76102
Yes No No No
1433038 Tpg Advisors Vi, Inc. C/o Tpg Global, Llc
301 Commerce Street, Suite 3300
Fort Worth TX 76102
Yes No No No
1495741 Tpg Group Holdings (Sbs) Advisors, Inc. C/o Tpg Global, Llc
301 Commerce Street, Suite 3300
Fort Worth TX 76102
Yes No No No
1666545 Tpg Biotech Advisors, Inc. C/o Tpg Global, Llc
301 Commerce Street, Suite 3300
Fort Worth TX 76102
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-08-08 2,616,028 $156.85 5,915,223 No 4 S Indirect See Explanation of Responses
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Explanation of Responses
Footnotes
  1. David Bonderman and James G. Coulter are sole shareholders of each of (i) TPG Group Holdings (SBS) Advisors, Inc. ("Group Advisors"), (ii) TPG Advisors VI, Inc. ("Advisors VI"), (iii) TPG Advisors V, Inc. ("Advisors V") and (iv) TPG Biotech Advisors, Inc. ("Biotech Advisors" and, together with Group Advisors, Advisors VI, Advisors V and Messrs. Bonderman and Coulter, the "Reporting Persons").
  2. Group Advisors is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar V Advisors, LLC, (ii) TPG GenPar VI Advisors, LLC and (iii) TPG Biotechnology GenPar III Advisors, LLC. TPG GenPar V Advisors, LLC is the general partner of TPG GenPar V, L.P., which is the general partner of each of (i) TPG Partners V, L.P., which directly holds 2,115,281 shares of Common Stock ("Common Stock") of IQVIA Holdings Inc. (the "Issuer"), (ii) TPG FOF V-A, L.P., which directly holds 5,534 shares of Common Stock, and (iii) TPG FOF V-B, L.P., which directly holds 4,462 shares of Common Stock.
  3. TPG GenPar VI Advisors, LLC is the general partner of TPG GenPar VI, L.P., which is the general partner of TPG Partners VI, L.P., which directly holds 2,116,908 shares of Common Stock. TPG Biotechnology GenPar III Advisors, LLC is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P., which directly holds 87,340 shares of Common Stock. Advisors VI is the (i) general partner of TPG FOF VI SPV, L.P., which directly holds 8,368 shares of Common Stock, and (ii) managing member of TPG Iceberg Co-Invest LLC, which directly holds 727,835 shares of Common Stock.
  4. Advisors V is the general partner of TPG Quintiles Holdco II, L.P., which directly holds 807,253 shares of Common Stock. Biotech Advisors is the general partner of TPG Quintiles Holdco III, L.P. (together with TPG Partners V, L.P., TPG FOF V-A, L.P., TPG FOF V-B, L.P., TPG Partners VI, L.P., TPG Biotechnology Partners III, L.P., TPG FOF VI SPV, L.P., TPG Iceberg Co-Invest LLC and TPG Quintiles Holdco II, L.P., the "TPG Funds"), which directly holds 42,242 shares of Common Stock.
  5. Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each Reporting Person and each of the TPG Funds disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's or such TPG Fund's pecuniary interest therein, if any.
  6. Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.